相似文献
1
Serum Antibody Profile of a Patient With Coronavirus Disease 2019 Reinfection.
Clin Infect Dis. 2021 May 18;72(10):e659-e662. doi: 10.1093/cid/ciaa1368.
2
Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection of a Healthcare Worker in a Belgian Nosocomial Outbreak Despite Primary Neutralizing Antibody Response.
Clin Infect Dis. 2021 Nov 2;73(9):e2985-e2991. doi: 10.1093/cid/ciaa1850.
3
A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection.
CEN Case Rep. 2022 Nov;11(4):422-427. doi: 10.1007/s13730-022-00697-z. Epub 2022 Mar 9.
4
Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
J Immunol. 2020 Nov 1;205(9):2437-2446. doi: 10.4049/jimmunol.2000717. Epub 2020 Sep 2.
5
SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies.
Viruses. 2021 Apr 12;13(4):661. doi: 10.3390/v13040661.
6
Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil.
Emerg Infect Dis. 2021 May;27(5):1446-1453. doi: 10.3201/eid2705.204912. Epub 2021 Apr 12.
7
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Pediatrics. 2020 Dec;146(6). doi: 10.1542/peds.2020-018242. Epub 2020 Sep 2.
8
A case with SARS-CoV-2 reinfection from India.
Indian J Med Microbiol. 2022 Jan-Mar;40(1):166-168. doi: 10.1016/j.ijmmb.2021.09.010. Epub 2021 Nov 15.
9
Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates.
Nat Biomed Eng. 2020 Dec;4(12):1188-1196. doi: 10.1038/s41551-020-00642-4. Epub 2020 Oct 29.
10
SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
J Infect Dis. 2021 Feb 24;223(4):589-599. doi: 10.1093/infdis/jiaa737.
引用本文的文献
1
Identification of Clinical and Genomic Features Associated with SARS-CoV-2 Reinfections.
Viruses. 2025 Jun 11;17(6):840. doi: 10.3390/v17060840.
2
Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
PLoS One. 2023 Sep 19;18(9):e0291670. doi: 10.1371/journal.pone.0291670. eCollection 2023.
3
Immune landscape and redox imbalance during neurological disorders in COVID-19.
Cell Death Dis. 2023 Sep 6;14(9):593. doi: 10.1038/s41419-023-06102-6.
4
Clinical and epidemiological features of patients with COVID-19 reinfection: a systematic review.
New Microbes New Infect. 2022 Jul;48:101021. doi: 10.1016/j.nmni.2022.101021. Epub 2022 Aug 28.
5
SARS-CoV-2 reinfection across a spectrum of immunological states.
Health Sci Rep. 2022 Jul 22;5(4):e554. doi: 10.1002/hsr2.554. eCollection 2022 Jul.
6
Association between Recent Usage of Antibiotics and Immunogenicity within Six Months after COVID-19 Vaccination.
Vaccines (Basel). 2022 Jul 14;10(7):1122. doi: 10.3390/vaccines10071122.
7
COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants.
Vaccines (Basel). 2022 Jun 6;10(6):905. doi: 10.3390/vaccines10060905.
8
Clinical Characteristics and Outcomes of Patients With SARS-CoV-2 Reinfection.
Mayo Clin Proc Innov Qual Outcomes. 2022 Aug;6(4):361-372. doi: 10.1016/j.mayocpiqo.2022.05.004. Epub 2022 May 30.
9
Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.
Perm J. 2021 Oct 29;26(1):123-131. doi: 10.7812/TPP/21.035.
10
COVID-19 Vaccines and Public Anxiety: Antibody Tests May Be Widely Accepted.
Front Public Health. 2022 May 6;10:819062. doi: 10.3389/fpubh.2022.819062. eCollection 2022.
Zotero 插件